Navigation Links
Gene Governs Response to Leukemia Chemotherapy
Date:1/7/2009

Acute lymphoblastic leukemia is most common pediatric cancer

WEDNESDAY, Jan. 7 (HealthDay News) -- A mutation in leukemia cells predicts which children with acute lymphoblastic leukemia are more likely to relapse.

The discovery, reported online Jan. 7 in the New England Journal of Medicine, might lead to tests to help physicians fine-tune treatment for different subsets of patients.

"The treatment of acute lymphoblastic leukemia (ALL) is really one of the success stories in American and international medicine in that close to 80 percent of patients can be cured with an intensive and prolonged chemotherapy regimen," said Dr. Arthur Frankel, a professor of medicine at the Texas A&M Health Science Center College of Medicine, who was not involved with the study.

"Having said that," Frankel added, "there are two changes that would improve the quality of care and maybe improve quality of life and the cure rate. One is that you'd like to identify patients that don't need this two years of aggressive chemotherapy. At the same time, there is a need for identifying early those children and adults that would do very poorly and trying to come up with new treatments."

ALL, or cancer of white blood cells called leukocytes, is the most common pediatric cancer.

Although current therapies are effective in a majority of pediatric patients, they can be hard to endure. And still, about 20 percent of patients will relapse, and only about a third of those who relapse will survive beyond five years.

Scientists have already identified a number of genetic mutations and deletions in genes (including the one that's the subject of the new report, IKAROS) that regulate the normal development of leukocytes, said study senior author Dr. James R. Downing, scientific director of St. Jude Children's Research Hospital, in Memphis, Tenn.

"But in prior studies, we never really saw any association with outcome," Downing said.

Downing and his colleagues conducted gene analyses of 221 children with high-risk ALL who were being treated for the disease as part of another study.

Deletions or changes in the IKAROS gene (of which there were several) that were found in slightly more than one-quarter of the patients were associated with a worse outcome. The findings were validated in a second group of 258 children.

IKAROS produces the IKAROS protein, which is involved in regulating other genes.

"The mutations of IKAROS were shown to be independent prognostic indicators, they had high value to identify patients at high risk of relapse over and above known risk factors," Downing said. "Identification of these lesions at the time of diagnosis would provide new information to better identify those patients."

It's unknown how the gene works at this point, but Downing speculated that it has to do with the gene's role in regulating the formation of lymphocyte cells.

Diagnostic tests need to be developed before the study results -- which also need to be replicated -- can be of benefit to patients, the researchers said.

There's another potential benefit down the road: new information to help find new targets for drugs.

More information

Visit the U.S. National Cancer Institute for more on ALL in children.



SOURCES: James R. Downing, M.D., scientific director, St. Jude Children's Research Hospital, Memphis, Tenn.; Arthur Frankel, M.D., professor, medicine, Texas A&M Health Science Center College of Medicine, and director, Cancer Center, Cancer Research Institute and Division of Hematology/Oncology, Scott & White Hospital, Jan. 7, 2009, New England Journal of Medicine, online


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Specific Brain Region Governs Problem-Solving Skills
2. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
3. Study identifies key player in the bodys immune response to chronic stress
4. Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911.
5. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
6. Merck & Co., Inc. Response to Todays New York Medicaid Suit
7. Maternal depression and controlling behavior associated with increased stress response in infants
8. Family history of alcoholism affects response to drug used to treat heavy drinking
9. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
10. Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer
11. PET scans can accurately detect a breast tumors response to chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical ... be the preferred physical therapy provider for Derby City CrossFit, effective immediately. , ... CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will work ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... to compare student test score performance for the 2015-16 school year across Wisconsin’s ... voucher programs. Though it highlights important patterns in student test score performance, the ...
(Date:4/25/2017)... Switzerland (PRWEB) , ... April 25, 2017 , ... ... innovation targets, they rely on contracted partners to help with process innovation in ... of combined drug formulation experience along with state-of-the-art analytical equipment in support of ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to ... of acute or chronic problems, I focus on preventative care with all my patients to ... have any questions, always feel free to contact my office and my trained staff will ...
(Date:4/25/2017)... ... , ... Vetoquinol USA® , a world-class developer of ... the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin ... , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DALLAS , April 19, 2017 /PRNewswire/ ... that the first patients in Nashville ... in the Lower Esophageal Sphincter Stimulation for GERD (LESS ... device designed to provide long-term reflux control by restoring ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)...  New research provides evidence that an old drug may ... study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... disease, the oral drug levodopa has long been considered the ... the disease progresses, the effects of the medication can partially ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device ... markets with innovative and proprietary products, will release financial ... after the market close on Tuesday, May 2, 2017. ... call and webcast to discuss its financial results the ... p.m. Eastern Time (3:30 p.m. Central Time). Darin ...
Breaking Medicine Technology: